Theratechnologies (THTX) Competitors $1.22 +0.02 (+1.67%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends THTX vs. MOLN, CYBN, MGNX, SOPH, ZNTL, GNFT, SLN, INBX, ZURA, and EDITShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Molecular Partners (MOLN), Cybin (CYBN), MacroGenics (MGNX), SOPHiA GENETICS (SOPH), Zentalis Pharmaceuticals (ZNTL), Genfit (GNFT), Silence Therapeutics (SLN), Inhibrx (INBX), Zura Bio (ZURA), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. Molecular Partners Cybin MacroGenics SOPHiA GENETICS Zentalis Pharmaceuticals Genfit Silence Therapeutics Inhibrx Zura Bio Editas Medicine Theratechnologies (NASDAQ:THTX) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Which has stronger earnings & valuation, THTX or MOLN? Theratechnologies has higher revenue and earnings than Molecular Partners. Theratechnologies is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$81.76M0.69-$23.96M-$0.10-12.20Molecular Partners$7.84M26.76-$69.04M-$2.15-2.42 Does the media refer more to THTX or MOLN? In the previous week, Theratechnologies had 1 more articles in the media than Molecular Partners. MarketBeat recorded 1 mentions for Theratechnologies and 0 mentions for Molecular Partners. Theratechnologies' average media sentiment score of 1.95 beat Molecular Partners' score of 0.00 indicating that Theratechnologies is being referred to more favorably in the media. Company Overall Sentiment Theratechnologies Very Positive Molecular Partners Neutral Is THTX or MOLN more profitable? Theratechnologies has a net margin of -3.75% compared to Molecular Partners' net margin of -1,043.01%. Theratechnologies' return on equity of 0.00% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-3.75% N/A -4.31% Molecular Partners -1,043.01%-39.31%-35.46% Do analysts rate THTX or MOLN? Molecular Partners has a consensus price target of $4.50, indicating a potential downside of 13.46%. Given Molecular Partners' higher probable upside, analysts plainly believe Molecular Partners is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Molecular Partners 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer THTX or MOLN? Theratechnologies received 17 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 52.73% of users gave Theratechnologies an outperform vote while only 46.15% of users gave Molecular Partners an outperform vote. CompanyUnderperformOutperformTheratechnologiesOutperform Votes2952.73% Underperform Votes2647.27% Molecular PartnersOutperform Votes1246.15% Underperform Votes1453.85% Do institutionals and insiders believe in THTX or MOLN? 26.6% of Molecular Partners shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, THTX or MOLN? Theratechnologies has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. SummaryTheratechnologies beats Molecular Partners on 12 of the 18 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.18M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-12.205.5697.3414.18Price / Sales0.69348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book-2.717.885.805.12Net Income-$23.96M$153.61M$119.07M$225.99M7 Day Performance0.83%-2.00%-1.83%-1.32%1 Month Performance-10.29%-7.47%-3.64%0.60%1 Year Performance-12.23%31.80%31.62%26.23% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$1.22+1.7%N/A-10.3%$55.18M$81.76M-12.20140Positive NewsMOLNMolecular Partners0.2312 of 5 stars$5.20-4.8%$4.50-13.5%+19.8%$220.24M$7.84M0.00180CYBNCybin1.4678 of 5 stars$11.14+1.2%$138.00+1,139.3%N/A$219.91MN/A-1.6750Analyst ForecastAnalyst RevisionGap UpMGNXMacroGenics3.8708 of 5 stars$3.28-5.7%$7.63+132.5%-57.0%$218.42M$58.75M0.00430SOPHSOPHiA GENETICS1.4237 of 5 stars$3.17-3.1%$6.50+105.0%-14.6%$213.78M$62.37M0.00520ZNTLZentalis Pharmaceuticals2.5896 of 5 stars$3.13+4.7%$10.00+219.5%-71.1%$213.08MN/A0.00160Analyst RevisionGNFTGenfit1.4608 of 5 stars$4.31+1.2%$13.00+201.6%+27.1%$212.95M$41.31M0.00120SLNSilence Therapeutics3.646 of 5 stars$6.93-0.6%$57.20+725.4%-27.1%$208.60M$31.55M0.00100Analyst ForecastNews CoverageHigh Trading VolumeINBXInhibrx1.2884 of 5 stars$14.04-1.7%N/A-36.9%$206.86M$1.63M0.00166ZURAZura Bio3.9055 of 5 stars$2.90-7.9%$15.80+444.8%-35.1%$205.68MN/A0.003Analyst ForecastEDITEditas Medicine4.7809 of 5 stars$2.41-2.8%$9.08+276.9%-77.8%$204.72M$78.12M-0.94230Short Interest ↓ Related Companies and Tools Related Companies MOLN Competitors CYBN Competitors MGNX Competitors SOPH Competitors ZNTL Competitors GNFT Competitors SLN Competitors INBX Competitors ZURA Competitors EDIT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
